ADHD Alcobra Ltd. - Ordinary Shares

+0.01  (1.01%)
Previous Close 0.99
Open 0.99
Price To book 0.52
Market Cap 27.56M
Shares 27,562,000
Volume 829,839
Short Ratio 2.69
Av. Daily Volume 561,703

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 17, 2017 - failed to meet primary endpoint.
MDX (Metadoxine Extended Release (MG01CI))
Adult ADHD
Phase 2b data released March 2015. Secondary cognitive measures did not produce statistically significant results.
MDX (Metadoxine Extended Release (MG01CI))
Pediatric ADHD
Phase 2 trial did not meet endpoints - June 2015.
MDX (Metadoxine Extended Release (MG01CI))
Fragile X Syndrome

Latest News

  1. Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA
  2. Alcobra Leads Biotech Movers Early Friday
  3. SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm
  4. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Alcobra Ltd.
  5. Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
  6. Alcobra Ltd (ADHD): Here’s Our Take
  7. Alcobra Stock Plunges 50% on Failed ADHD Drug
  8. Alcobra Pharma downgraded by Jefferies
  9. SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Alcobra, Ltd. and Advises Investors with Losses to Contact the Firm
  10. INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Alcobra Ltd. Investors
  11. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alcobra Ltd. (ADHD)
  12. DryShips, Alcobra Sink into Tuesday’s 52-Week Low Club
  13. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alcobra Ltd. - ADHD
  14. Alcobra Shares Plummet as ADHD Drug Fails
  15. Tuesday’s Top Biopharma Movers
  16. Alcobra to stop testing sole drug for ADHD after study fails
  17. Alcobra Ltd. stock plummets 43% after failed late-stage trial for its ADHD drug
  18. Alcobra's ADHD drug fails late-stage study
  19. Alcobra Reports Phase 3 Clinical Trial of MDX in Adults with ADHD Missed Primary Endpoint
  20. Monday’s 4 Biggest Biopharma Movers